

Claims

1. A compound having the structure of Formula (IVa) or (IVb):



(IVa)





(IVb)

or a pharmaceutically acceptable salt thereof, wherein,

R^3 is selected from hydrogen and $C_{1\text{-}6}$ alkyl;

X is–CH_3; and

R^4 is selected from amino $C_{1\text{-}6}$ alkyl, $–R^{4a}NHCOR^{4b}$, $C_{1\text{-}6}$ heterocyclyl, substituted $C_{1\text{-}6}$ alkyl, substituted amino $C_{1\text{-}6}$ alkyl, and substituted $C_{1\text{-}6}$ heterocyclyl, wherein the substituent group is selected from $C_{1\text{-}6}$ alkyl, $–NH_2$, oxo(=O), $C_{1\text{-}6}$ hydroxyalkyl, 

, and 


;

R^{4a} is $C_{1\text{-}6}$ alkylene; and


R^{4b} is selected from $C_{1\text{-}6}$ alkyl and $C_{1\text{-}6}$ haloalkyl.


2. The compound of claim 1, wherein R^4 is selected from $C_{1\text{-}6}$ heterocyclyl, andsubstituted $C_{1\text{-}6}$ heterocyclyl.


3. The compound of claim 1, wherein the $C_{1\text{-}6}$ heterocyclyl is selected from:



,


, 


, 


, and 


.


4. The compound of claim 1, wherein the compound is selected from:





















































































































Cl
O
O
O
O
N
X
O















































wherein X is–CH_3.


5. The compound of claim 1, wherein the compound is selected from A-3, A-4, A-12, A-20, A-27, A-37, A-51, A-55, and A-58:


A-3	

A-4	

A-20	
A-37	
A-55	
A-58	


6. The compound of claim 1, wherein the compound is: selected from 1-((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (A-3) and 1-((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (A-60):






or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein the compound is selected from 1-((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (A-4) and 1-((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (A-61):




or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1, wherein the compound is selected from (*S*)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (A-20) and (*R*)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (A-64):




or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, wherein the compound is selected from ((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-*L*-valinate (A-37) and ((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-*L*-valinate (A-67):




or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1, wherein the compound is selected from 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (A-55) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (A-59):



or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, wherein the compound is selected from 1-((((*S*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (A-58) and 1-((((*R*)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (A-70):



or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is an oral formulation.

14. Use of the compound of any one of claims 1 to 11 or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 12 to 13 in the manufacture of a medicament for treating pain.

15. Use of the compound of any one of claims 1 to 11 or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 12 to 13 in the manufacture of a medicament for treating depression.

16. Use of the compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 12 to 13 in the manufacture of a medicament for treating a neurological disorder or disease of the central nervous system associated with NMDA receptor inhibition.

17. Use of the compound of any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 12 to 13 in the manufacture of a

medicament for treating a psychiatric disorder or disease of the central nervous system associated with NMDA receptor inhibition.